Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
about
Ubiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and Bmi1 and cellular response to gemcitabineA phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignanciesA phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.Targeted therapies for pancreatic cancer.The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsBortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors.Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatinActive roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicinVelcade combinations in mantle cell lymphoma: are we learning anything?
P2860
Q28540690-988ED55E-7D95-4FD4-A4C3-FBE2EF0E0C51Q33394153-01A9B4CD-AB3E-4DE2-9513-D3860F13545CQ33396761-39102260-2F5E-4619-BFC5-0B5FB3F2CD43Q33398947-7D5231BE-8B2A-4B64-9873-B376C919D782Q33409608-ED192613-1088-4606-B731-FCD80EA25350Q33899923-4956AECE-6F5B-495B-BBBB-0C1862EB3797Q33916030-C1CCD6EB-97EF-49E6-88A7-9A6CAF0102CFQ35005087-CF51CD24-F21D-49A2-8956-449C47E49986Q37017342-1F3F337D-B883-4CDB-A56D-92E8C9B64ADBQ37326210-AECED43A-B857-4899-9E5E-C1FC4C1C8012Q37414098-8D02A3E2-4DB7-464A-B422-01850AFE32BBQ37856761-DEBCB1D3-E594-467B-BB9F-D73CFD3AAE30Q39710105-A028CB57-3CD2-48EA-B926-3567065FE0AFQ39958680-924DE924-3009-41B4-8574-F7CB5BED3A7EQ51876606-3965C528-5A0D-4F40-B1C9-18CAA10DDD4A
P2860
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Phase I clinical trial of bort ...... ts with advanced solid tumors.
@ast
Phase I clinical trial of bort ...... ts with advanced solid tumors.
@en
type
label
Phase I clinical trial of bort ...... ts with advanced solid tumors.
@ast
Phase I clinical trial of bort ...... ts with advanced solid tumors.
@en
prefLabel
Phase I clinical trial of bort ...... ts with advanced solid tumors.
@ast
Phase I clinical trial of bort ...... ts with advanced solid tumors.
@en
P2093
P356
P1433
P1476
Phase I clinical trial of bort ...... ts with advanced solid tumors.
@en
P2093
Andrew X Zhu
David P Ryan
James Cusack
Jeffrey G Supko
Jeffrey W Clark
Joseph P Eder
Mayer Fishman
Oscar Kashala
Panagiotis Fidias
Peter C Enzinger
P304
P356
10.1002/CNCR.22264
P407
P577
2006-11-01T00:00:00Z